The Latest News
Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System at CIRSE
Surefire Medical, Inc. has announced the launch of the company’s new precision targeted delivery infusion system for direct-to-tumor embolization procedures. The new technology was displayed at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015 Scientific Meeting in Lisbon, Portugal. Surefire infusion systems are used by interventional radiologists and oncologists in minimally invasive primary and secondary liver cancer treatments. “Chemo- and radioembolization techniques are becoming valuable treatment options in selected patients with unresectable liver tumors. The Precision catheter provides us with a new interventional tool to safely and effectively deliver drug eluting and yttrium-90 microspheres within the tumor,” said Professor Dr. G. Maleux, Department of Radiology of the University Hospitals Leuven, Belgium. The Precision addresses a clear need in the ability to treat primary liver cancers, 80 percent of which are inoperable, and may help lower the overall costs of treatment.
SureFire is a portfolio company of Tullis Growth Fund, L.P., (“TGF”). In addition to its position on the board of directors, the Tullis team has also been working with the company on their international commercial expansion. John Tullis, Surefire Board Member, is investigating the entry of Surefire into the international marketplace, especially China. More than 50% of primary liver cancer cases globally are in China. Surefire’s revenue has now achieved a run rate above $5 million annually and is growing quickly. Its products and technologies are now used in over 100 hospitals in the U.S. and14 countries around the world.